fool.com · 10 jul

3 Under-the-Radar Stocks to Buy and Hold

These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.

fool.com · 9 jul

Better Growth Buy: Axsome vs Revolution Medicines

Axsome has a solid late-stage pipeline and growing commercialized drugs. Revolution aims to revolutionize cancer treatment, and a recent phase 3 trial shows it may be on the right path.

zacks.com · 8 jul

Axsome Begins Phase III Study on Solriamfetol for ADHD in Children

AXSM doses the first patient in the phase III FOCUS-2 study of solriamfetol for treating ADHD in children aged six to under 12 years.

globenewswire.com · 7 jul

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the FOCUS-2 Phase 3 trial evaluating solriamfetol as a treatment for children with attention deficit hyperactivity disorder (ADHD). FOCUS-2 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol in children aged 6 to less than 12 years with ADHD.

fool.com · 6 jul

These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More

Each of these biotech players has reached an important turning point. Recent drug approvals could supercharge the performance of one in particular.

fool.com · 2 jul

Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say.

Axsome specializes in central nervous system disorders, including depression, migraine, and fibromyalgia. Axsome's Auvelity recently won approval to treat agitation associated with Alzheimer's disease.

forbes.com · 1 jul

Why Axsome Stock Has Doubled In Nine Months

In this week's edition of InnovationRx, we look at Axsome's growing pipeline, HistoSonics innovative cancer treatment, state litigation over Medicaid work requirements, and more. To get it in your inbox, subscribe here.

globenewswire.com · 26 jun

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the FOCUS-3 Phase 3 trial evaluating solriamfetol as a treatment for adolescents with attention deficit hyperactivity disorder (ADHD).